Healthy Volunteers
Conditions
Keywords
BMS-986419, healthy, QTC, pharmacokinetics, moxifloxacin
Brief summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
Interventions
DRUGBMS-986419
Specified dose on specified days
DRUGBMS-986419 Matching Placebo
Specified dose on specified days
DRUGMoxifloxacin
Specified dose on specified days
DRUGMoxifloxacin Matching Placebo
Specified dose on specified days
Sponsors
Bristol-Myers Squibb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments. * Participants must have a Body mass index (BMI) between 18.0 and 30.0 kilograms/meter square (kg/m\^2), inclusive, at screening.
Exclusion criteria
* Participants must not have any significant acute or chronic medical illness as determined by the investigator. * Participants must not have any current or recent (within 3 months of study intervention administration) GI disease, liver and kidney that could possibly affect drug absorption, distribution, metabolism, and excretion, (e.g., bariatric procedure, Cholecystectomy, and any other GI surgery that could impact upon the absorption of study intervention). * Participants must not have Gilbert Syndrome. * Participants must not have a history of clinically relevant cardiac disease as determined by the investigator, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for ventricular arrhythmias (e.g., long QT syndrome, catecholamine polymorphic ventricular tachycardia). * Participants must not have exposure to any investigational drug or placebo (other than BMS-986419 or moxifloxacin) within 4 weeks or 5 half-lives (whichever is longer) prior to Day -1 (Day -2 for Part 2) until follow-up phone call. * Other protocol-defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1: Number of Participants with Non-serious Adverse Events (NSAEs) | Up to approximately Day 42 | — |
| Part 1: Number of Participants with Serious Adverse Events (SAEs) | Up to approximately Day 42 | — |
| Part 1: Number of Participants with AEs Leading to Discontinuation | Up to approximately Day 42 | — |
| Part 1: Number of Participants With AEs of Special Interest (AESI) | Up to approximately Day 42 | — |
| Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities | Up to approximately Day 21 | Vital sign parameters include temperature, systolic blood pressure (BP), diastolic BP, respiratory rate, and heart rate (HR) assessment. |
| Part 1: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities | Up to approximately Day 21 | — |
| Part 1: Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | Up to approximately Day 21 | — |
| Part 1: Number of Participants With Clinically Significant Columbia-Suicide Severity Rating Scale (C-SSRS) Abnormalities | Up to approximately Day 21 | — |
| Part 1: Number of Participants With Clinically Significant Neurological Examination Abnormalities | Up to approximately Day 21 | — |
| Part 1: Number of Participants With Physical Examination Abnormalities | Up to approximately Day 21 | — |
| Part 2: ΔQTc: Change From Baseline in Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QT interval (QTc) | Up to approximately Day 15 | ΔQTc is performed by primary correction. |
| Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QTc | Up to approximately Day 15 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Pulse Rate (PR)(ΔPR) Correction | Up to approximately Day 15 | — |
| Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Respiratory Rate (RR) Interval Correction | Up to approximately Day 15 | — |
| Part 2: Change From Baseline of BMS-986419 in Quality Rating System (QRS) Interval (ΔQRS) | Up to approximately Day 15 | — |
| Part 2: Number of Participants With Treatment-emergent Values of Fridericia's Corrected QT interval (QTcF) for BMS-986419 | Up to approximately Day 15 | Participants with increase in absolute treatment-emergent QTc values \>450 and ≤480 milliseconds (msec), \>480 and ≤500 msec, or \>500 msec, and changes from pre-dose baseline of \>30 and ≤ 60 msec, or \>60 msec will be measured. |
| Part 2: Number of Timepoints With Change in Absolute Treatment-emergent QTcF Values for BMS-986419 | Up to approximately Day 15 | Number of timepoints with increase in absolute treatment-emergent QTc values \>450 and ≤480 milliseconds (msec), \>480 and ≤500 msec, or \>500 msec, and changes from pre-dose baseline of \>30 and ≤ 60 msec, or \>60 msec will be measured. |
| Part 2: Number of Participants With Treatment-emergent Values of HR for BMS-986419 | Up to approximately Day 15 | Participants with decrease in HR from pre-dose baseline \>25% to a HR \<50 beats per minute (bpm); and increase in HR from pre-dose baseline \>25% to a HR \>100 bpm will be determined. |
| Part 2: Number of Timepoints With Change in Absolute Treatment-emergent HR Values for BMS-986419 | Up to approximately Day 15 | Number of timepoints with decrease in HR from pre-dose baseline \>25% to a HR \<50 beats per minute (bpm); and increase in HR from pre-dose baseline \>25% to a HR \>100 bpm will be determined. |
| Part 2: Number of Participants With Treatment-emergent Values of PR for BMS-986419 | Up to approximately Day 15 | Participants with increase in PR from pre-dose baseline \>25% to a PR\>200 msec will be determined. |
| Part 2: Number of Timepoints With Increase in Absolute Treatment-emergent PR Values for BMS-986419 | Up to approximately Day 15 | Number of timepoints with increase in PR from pre-dose baseline \>25% to a PR\>200 msec will be determined. |
| Part 2: Number of Participants With Treatment-emergent Values of QRS for BMS-986419 | Up to approximately Day 15 | Participants with increase in QRS from pre-dose baseline \>25% to a QRS \>120 msec will be determined. |
| Part 2: Number of Timepoints With Increase in Absolute Treatment-emergent QRS Values for BMS-986419 | Up to approximately Day 15 | Number of timepoints with increase in QRS from pre-dose baseline \>25% to a QRS \>120 msec will be determined. |
| Part 2: AI_AUC(TAU) of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: Number of Participants With New Onset ECG Morphology Findings | Up to approximately Day 15 | New means an ECG finding that is not present on any baseline ECG \[that is, any ECG recorded prior to receipt of the first dose of study BMS-986419\] and becomes present on at least 1 on-treatment ECG during that treatment period). |
| Part 2: ΔQTc: Change From Baseline in Plasma Concentration of Moxifloxacin on Cardiac Repolarization Expressed by QT interval (QTc) | Up to approximately Day 15 | ΔQTc is performed by primary correction. |
| Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of Moxifloxacin on Cardiac Repolarization Expressed by QTc | Up to approximately Day 15 | — |
| Part 2: Number of Participants with NSAEs | Up to approximately Day 36 | — |
| Part 2: Number of Participants with SAEs | Up to approximately Day 36 | — |
| Part 2: Number of Participants with AEs Leading to Discontinuation | Up to approximately Day 36 | — |
| Part 2: Number of Participants With AESI | Up to approximately Day 36 | — |
| Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities | Up to approximately Day 15 | Vital sign parameters include temperature, systolic BP, diastolic BP, respiratory rate, and HR assessment. |
| Part 2: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities | Up to approximately Day 14 | — |
| Part 2: Number of Participants With Clinically Significant 12-Lead ECG Abnormalities | Up to approximately Day 15 | — |
| Part 2: Number of Participants With Clinically Significant C-SSRS Abnormalities | Up to approximately Day 15 | — |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of BMS-986419 | Up to approximately Day 21 | — |
| Part 2: Number of Participants With Physical Examination Abnormalities | Up to approximately Day 15 | — |
| Part 2: Cmax of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: Tmax of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: AUC(0-T) of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: AUC(TAU) of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: T-Half of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: AI_Cmax of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: Trough Concentration of BMS-986419 | Up to approximately Day 15 | — |
| Part 2: Number of Participants With Clinically Significant Neurological Examination Abnormalities | Up to approximately Day 15 | — |
| Part 1: Time of Maximum Plasma Observed Concentration (Tmax) of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU)) of BMS-986419 | Up to approximately Day 21 | — |
| Part 2: Number of Participants With Treatment-emergent Values of Individualized Heart Rate-corrected Interval/Optimized HR-corrected QT Interval (QTcS/QTcI) for BMS-986419 | Up to approximately Day 15 | — |
| Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-T]) of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Terminal Phase Elimination Half-life (T-Half) of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax) of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)] of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Apparent Total Body Clearance (CLT/F) of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Apparent Volume of Distribution of Terminal Phase (Vz/F) of BMS-986419 | Up to approximately Day 21 | — |
| Part 1: Trough Concentration of BMS-986419 | Up to approximately Day 21 | — |
| Part 2: ΔQTc of BMS-986419 Using Change From Baseline of Heart Rate (HR)(ΔHR) Correction | Up to approximately Day 15 | — |
Countries
United States
Outcome results
None listed